CN110121357A - 一种治疗糖尿病的新方法 - Google Patents

一种治疗糖尿病的新方法 Download PDF

Info

Publication number
CN110121357A
CN110121357A CN201780078131.3A CN201780078131A CN110121357A CN 110121357 A CN110121357 A CN 110121357A CN 201780078131 A CN201780078131 A CN 201780078131A CN 110121357 A CN110121357 A CN 110121357A
Authority
CN
China
Prior art keywords
plasminogen
subject
secretion
expression
diabetic subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078131.3A
Other languages
English (en)
Chinese (zh)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN110121357A publication Critical patent/CN110121357A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780078131.3A 2016-12-15 2017-06-19 一种治疗糖尿病的新方法 Pending CN110121357A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110171 2016-12-15
CNPCT/CN2016/110171 2016-12-15
PCT/CN2017/089062 WO2018107702A1 (zh) 2016-12-15 2017-06-19 一种治疗糖尿病的新方法

Publications (1)

Publication Number Publication Date
CN110121357A true CN110121357A (zh) 2019-08-13

Family

ID=62557852

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078131.3A Pending CN110121357A (zh) 2016-12-15 2017-06-19 一种治疗糖尿病的新方法
CN201780078124.3A Pending CN110139667A (zh) 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法
CN201780078122.4A Pending CN110366426A (zh) 2016-12-15 2017-06-19 一种促进胰岛素分泌的方法
CN201780078168.6A Pending CN110198732A (zh) 2016-12-15 2017-06-19 一种促进胰岛素受体底物-2表达的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780078124.3A Pending CN110139667A (zh) 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法
CN201780078122.4A Pending CN110366426A (zh) 2016-12-15 2017-06-19 一种促进胰岛素分泌的方法
CN201780078168.6A Pending CN110198732A (zh) 2016-12-15 2017-06-19 一种促进胰岛素受体底物-2表达的方法

Country Status (9)

Country Link
US (4) US20190307861A1 (enExample)
EP (4) EP3556390B1 (enExample)
JP (6) JP7175270B2 (enExample)
CN (4) CN110121357A (enExample)
CA (4) CA3047177A1 (enExample)
DK (1) DK3556383T5 (enExample)
ES (1) ES2981141T3 (enExample)
TW (7) TWI763680B (enExample)
WO (7) WO2018107708A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
EP3556390B1 (en) * 2016-12-15 2024-04-03 Talengen International Limited Plasminogen for use in treating diabetes
US20190314466A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Method for preventing and treating skin fibrosis
TWI714862B (zh) * 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000420A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
WO2010125148A2 (en) * 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
WO1994001128A1 (en) 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (enExample) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
MX9708217A (es) 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5955627A (en) 1996-12-16 1999-09-21 Kuraray Co., Ltd. Process for the preparation of cyclopropylacetylene derivatives
JP3561154B2 (ja) 1997-12-26 2004-09-02 株式会社東芝 放送受信装置および契約管理装置
US6728260B2 (en) 1998-06-26 2004-04-27 Intel Corporation Switch and/or router unit
HK1041449B (zh) 1998-09-29 2005-08-19 勒芬研究与发展公司 可在體內減少α2-抗纖溶酶的化合物在製備用於治療局部缺血性中風的組合物中的用途
AU2974300A (en) 1999-01-28 2000-08-18 Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20030014787P1 (en) 1999-03-31 2003-01-16 Olesen L. Pernille Floribunda rose variety 'POULfeld'
WO2001024815A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US6596785B2 (en) 2001-07-17 2003-07-22 Foamex L.P. Ink retaining foam structure
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003210137A1 (en) 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US7075933B2 (en) 2003-08-01 2006-07-11 Nortel Networks, Ltd. Method and apparatus for implementing hub-and-spoke topology virtual private networks
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
EP2246417B1 (en) 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US8064439B2 (en) 2005-06-30 2011-11-22 Cisco Technology, Inc. Method and system for call processing
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) * 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
MX2009002226A (es) * 2006-08-28 2009-09-07 Omnio Healer Ab Candidatos contra infeccion.
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
WO2009073471A1 (en) * 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
AU2010270146B9 (en) 2009-07-10 2015-04-02 Thrombogenics Nv Variants of plasminogen and plasmin
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CN103384722B (zh) 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
WO2013024074A1 (en) * 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
WO2014070983A1 (en) 2012-10-31 2014-05-08 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
CN112142845A (zh) * 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
KR102393711B1 (ko) * 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
KR102692851B1 (ko) 2014-12-19 2024-08-06 프로메틱 바이오 테라퓨틱스 인코포레이티드 플라스미노겐을 포함하는 약학 조성물 및 이의 용도
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
DK3395359T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
EP3556390B1 (en) * 2016-12-15 2024-04-03 Talengen International Limited Plasminogen for use in treating diabetes
US20190328850A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating lipid metabolism disorders and related diseases thereof
EP3725326A4 (en) 2017-12-15 2021-03-03 Talengen International Limited METHODS AND MEDICINAL PRODUCTS FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000420A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
WO2010125148A2 (en) * 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARTHUR MIRSK等: "The destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
AURELIA LUGEA等: "Pancreas Recovery Following Caerulein-induced Pancreatitis is Impaired in Plasminogen Deficient Mice", 《GASTROENTEROLOGY》 *
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 *
RAMZI A. AJJAN等: "Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity" *
RAMZI A. AJJAN等: "Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity", 《BLOOD》 *
周汉明等: "纤溶酶辅助治疗2型糖尿病62例" *

Also Published As

Publication number Publication date
WO2018107703A1 (zh) 2018-06-21
JP2020502140A (ja) 2020-01-23
JP7175270B2 (ja) 2022-11-18
EP3556390A4 (en) 2020-09-09
EP3556390A1 (en) 2019-10-23
ES2981141T3 (es) 2024-10-07
CN110139667A (zh) 2019-08-16
EP3556383B1 (en) 2024-04-10
EP3556384A4 (en) 2020-09-23
EP3556390B1 (en) 2024-04-03
WO2018107706A1 (zh) 2018-06-21
EP3556384A1 (en) 2019-10-23
WO2018107701A1 (zh) 2018-06-21
TWI763680B (zh) 2022-05-11
TW201822803A (zh) 2018-07-01
CN110198732A (zh) 2019-09-03
EP3556384B1 (en) 2024-04-10
TWI738799B (zh) 2021-09-11
TWI644682B (zh) 2018-12-21
JP2020502151A (ja) 2020-01-23
TWI642442B (zh) 2018-12-01
US11311607B2 (en) 2022-04-26
WO2018107702A1 (zh) 2018-06-21
TW201822804A (zh) 2018-07-01
EP3556383A1 (en) 2019-10-23
TW201822807A (zh) 2018-07-01
US20190314465A1 (en) 2019-10-17
EP3556392B1 (en) 2024-04-17
CA3047176C (en) 2021-11-30
JP2022166026A (ja) 2022-11-01
JP2020502150A (ja) 2020-01-23
US20190314463A1 (en) 2019-10-17
CA3047173A1 (en) 2018-06-21
TW201822800A (zh) 2018-07-01
WO2018107704A1 (zh) 2018-06-21
CA3047176A1 (en) 2018-06-21
TWI669130B (zh) 2019-08-21
US11129880B2 (en) 2021-09-28
CN110366426A (zh) 2019-10-22
WO2018107708A1 (zh) 2018-06-21
CA3047172A1 (en) 2018-06-21
TW201822808A (zh) 2018-07-01
JP7554048B2 (ja) 2024-09-19
TW201822802A (zh) 2018-07-01
JP2020510628A (ja) 2020-04-09
JP2022166028A (ja) 2022-11-01
US20190314464A1 (en) 2019-10-17
DK3556383T5 (da) 2024-09-02
US20190307861A1 (en) 2019-10-10
EP3556392A1 (en) 2019-10-23
JP7554557B2 (ja) 2024-09-20
EP3556383A4 (en) 2020-09-09
JP7171572B2 (ja) 2022-11-15
TWI763681B (zh) 2022-05-11
DK3556383T3 (da) 2024-05-13
TW201822801A (zh) 2018-07-01
EP3556392A4 (en) 2020-09-23
WO2018107705A1 (zh) 2018-06-21
CA3047177A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
CN110121357A (zh) 一种治疗糖尿病的新方法
Janež et al. Insulin therapy in adults with type 1 diabetes mellitus: a narrative review
Hrynyk et al. Insulin and wound healing
Hanafusa et al. Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population
Van Gaal et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program
Kantarjian et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
KR101847485B1 (ko) 초속효성 인슐린의 용도
AU2011202239C1 (en) Long-acting formulations of insulins
Wahren C‐peptide: new findings and therapeutic implications in diabetes
Bassi et al. Impact of islet transplantation on diabetes complications and quality of life
JP2020502151A5 (enExample)
Nally et al. Pharmacologic treatment options for type 1 diabetes: what’s new?
US20250268944A1 (en) Stromal stem cell therapeutics and methods of use
JP2020502150A5 (enExample)
CN106117370A (zh) 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途
JP2020510628A5 (enExample)
Mulka et al. Phenolic preservative removal from commercial insulin formulations reduces tissue inflammation while maintaining euglycemia
Kaur et al. Translational aspects of glucagon: Current use and future prospects
EP3421989A1 (en) Test method
WO2024213005A1 (zh) 一种用于难愈性创面修复的药物
CN101766811B (zh) 艾塞那肽或其类似物在制备治疗或预防糖尿病合并脑梗塞药物中的用途
Riebenfeld et al. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain
Aloke et al. Current advances in the management of diabetes mellitus. Biomedicines 2022, 10, 2436
Oh et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis
Hernandez-Bastida et al. Equivalence on efficay and safety of two formulations of insulin glargine (biosimilar and reference) in the treatment of patients with type 2 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination